ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:VAL
Previous Symbol
CUSIPN/A
Phone+44-20-30084416
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees12
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable
ValiRx (LON:VAL) Frequently Asked Questions
What is ValiRx's stock symbol?
ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."
How were ValiRx's earnings last quarter?
ValiRx Plc (LON:VAL) announced its quarterly earnings results on Tuesday, April, 10th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.60) by $0.70. View ValiRx's Earnings History.
What price target have analysts set for VAL?
1 equities research analysts have issued 1 year target prices for ValiRx's stock. Their predictions range from £100,000 to GBX 0. On average, they expect ValiRx's stock price to reach GBX 0 in the next year. This suggests that the stock has a possible downside of 100.0%. View Analyst Price Targets for ValiRx.
What is the consensus analysts' recommendation for ValiRx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ValiRx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ValiRx.
Has ValiRx been receiving favorable news coverage?
News articles about VAL stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ValiRx earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the next few days.
Who are some of ValiRx's key competitors?
Some companies that are related to ValiRx include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE).
Who are ValiRx's key executives?
ValiRx's management team includes the folowing people:
- Dr. Satu Vainikka, Founding Director & Chief Exec. Officer (Age 51)
- Mr. James Gerry Desler, Founding Director & Chief Financial Officer (Age 62)
- Dr. George Morris, Founding Director & Chief Operating Officer (Age 62)
- Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 62)
- Tarquin Edwards, Head of Communications
How do I buy shares of ValiRx?
Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ValiRx's stock price today?
One share of VAL stock can currently be purchased for approximately GBX 1.35.
What is ValiRx's official website?
How can I contact ValiRx?
ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.
MarketBeat Community Rating for ValiRx (LON VAL)
MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe VAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days.
